SD-RAVEN-INDUSTRIES
15.6.2021 15:17:10 CEST | Business Wire | Press release
Raven Industries, Inc. (the Company; NASDAQ:RAVN), the leader in autonomous agriculture technology, announced today the purchase of a second OMNiPOWER™ platform by Haggerty AgRobotics. Raven’s driverless ag and precision technology deliver impactful solutions for local and enterprise farms as the agriculture industry’s labor shortages continue to grow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005181/en/
“Labor shortage concerns within our local growers have really elevated the need for more automation and robotics on the farm,” said Chuck Baresich, President of Haggerty AgRobotics.
Haggerty Creek Ltd., an establised company delivering grain and crop input needs for growers in Ontario, Canada, has been collaborating with Raven to solve industry challenges for over a decade. In 2020, Haggerty Creek Ltd. purchased its first OMNiPOWER and in 2021 purchased OMNiDRIVE to help farmers with operational challenges they face. The growing demand for driverless ag technology as an impactful solution for labor shortages pushed Baresich to launch Haggerty AgRobotics, a service focused entirely on autonomy, robotics and technology automation at the farm level.
The second OMNiPOWER platform will allow Haggerty AgRobotics to lead the industry as one of the first customers to implement a real-world fleet of autonomous machines. Baresich will now manage a fleet of OMNi platforms with machine-to-machine connectivity through the Viper® 4+ field computer. The integration of Raven’s advanced precision farming technology within the OMNiPOWER platform allows for a seamless user experience and real-time shared coverage visibility.
“As one of the first customers of this technology, we are very excited to bring Raven driverless ag solutions to the market in a big way,” said Baresich. “The recent updates and advancements to Raven’s technology are impressive and we have experienced incredible performance in our 2021 spring program. We purchased our second OMNiPOWER platform to continue to be on the leading edge of commercializing autonomous machines as an organized fleet.”
“Raven has made significant investments in our OMNi suite of driverless ag solutions,” said Ben Voss, Raven Applied Technology Director of Sales for North America and Australia. “It is exciting to see a progressive, ag-tech focused operation like Haggerty AgRobotics partner with us to showcase autonomy and precision applications in the agriculture market. OMNiPOWER and OMNiDRIVE position both of us as autonomy pioneers in the global agriculture industry.”
Raven unveiled their OMNi brand of autonomous solutions less than a month ago and is actively fulfilling orders for both OMNiPOWER and OMNiDRIVE™ units worldwide. OMNiPOWER™ is a self-propelled power platform that easily interchanges farm implements like a sprayer or spreader. This autonomous platform empowers ag professionals to perform multiple farm tasks simultaneously without a driver. Raven’s Path to Autonomy begins with precision farming products that reduce driver fatigue and graduates up to full driverless ag technology automation.
By investing in driverless ag technology, Raven continues to design solutions that reduce operating costs, decrease inputs, and improve yields for ag professionals around the world. Available to order today at RavenPrecision.com .
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) is dedicated to providing innovative, high-value products and solutions that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and lighter-than-air technologies. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, high performance, and unmatched service. For more information, visit https://ravenind.com .
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite, Raven Autonomy™, is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com .
About Haggerty Creek Ltd.
Haggerty Creek Ltd. was established in 2001 to fill a market need in Ontario’s four counties area, being Lambdon, Middlesex, Elgin and Kent counties. Located north of Bothwell, Ontario, Haggerty Creek provides whole farm solutions, starting with precision crop planning and application, and ending with grain handling and marketing. In response to the growing demand for driverless ag technology, the company launched Haggerty AgRobotics, positioning themselves as a pioneer in a growing industry. Learn more at https://haggertycreek.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005181/en/
Link:
Social Media:
https://www.facebook.com/ravenprecision/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom